https://www.pharmanow.live/latest-news/teva-fda-approval-degevma-denosumab-biosimilar-xgeva 2026-09-29T10:48:42+05:30 Pharma Now en 2026-09-29T00:00:00+05:30 Teva Wins FDA Nod For DEGEVMA, Completing Denosumab Portfolio Teva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/552a3bd9-6f93-409b-8099-e7273f6afdf7/01329135-0163-415c-8b8a-60f4d2bacba7.png https://www.pharmanow.live/latest-news/boothwyn-pharmacy-fda-warning-letter-sterility-potency-failures-2026 2026-09-29T10:49:48+05:30 Pharma Now en 2026-09-29T00:00:00+05:30 FDA Warns Boothwyn Pharmacy Over Sterility, Potency Issues FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/552a3bd9-6f93-409b-8099-e7273f6afdf7/2a63bf98-0df2-4754-acc8-a06df290db37.png https://www.pharmanow.live/latest-news/oryzon-ema-cta-vafidemstat-hope-2-phelan-mcdermid-syndrome 2026-09-29T10:41:54+05:30 Pharma Now en 2026-09-28T00:00:00+05:30 Oryzon Gains Ema Cta For Vafidemstat Phase Ii Pms Study Oryzon https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/oryzon-genomics-vafidemstat-hope-2-phelan-mcdermid-syndrome-202620260929103927.webp https://www.pharmanow.live/latest-news/inventiva-nativ3-phase-3-topline-results-lanifibranor-mash-2026 2026-09-29T10:36:25+05:30 Pharma Now en 2026-09-28T00:00:00+05:30 Inventiva Awaits Phase 3 Nativ3 Data For Lanifibranor Inventiva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/inventiva-nativ3-phase-3-lanifibranor-mash-results-202620260929103452.webp